Evidence map›Paper›PMID 25356874›Full record

ArticleCell death & disease2014

Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.

C R R Rocha, C C M Garcia, D B Vieira, A Quinet, L C de Andrade-Lima, V Munford, J E Belizário, C F M Menck

Erratum issuedAbstract read
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed.

  1. Article
  2. NRF2 signaling drives chemoresistance in NSCLC and glioblastoma.Molecular and cellular biochemistry · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  18. Review
  19. Cisplatin in Liver Cancer Therapy.International journal of molecular sciences · 2023
    Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

C R R RochaDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulao, Av. Prof. Lineu Prestes, 1374, São Paulo 05505-900, Brazil.
C C M GarciaDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulao, Av. Prof. Lineu Prestes, 1374, São Paulo 05505-900, Brazil.
D B VieiraDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulao, Av. Prof. Lineu Prestes, 1374, São Paulo 05505-900, Brazil.
A QuinetDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulao, Av. Prof. Lineu Prestes, 1374, São Paulo 05505-900, Brazil.
L C de Andrade-LimaDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulao, Av. Prof. Lineu Prestes, 1374, São Paulo 05505-900, Brazil.
V MunfordDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulao, Av. Prof. Lineu Prestes, 1374, São Paulo 05505-900, Brazil.
J E BelizárioDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1374, São Paulo 05508-900, Brazil.
C F M MenckDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulao, Av. Prof. Lineu Prestes, 1374, São Paulo 05505-900, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy. The main chemotherapy protocol for this type of tumor is based on temozolomide (TMZ), albeit with limited success. Cisplatin is widely used to treat several types of tumor and, in association with TMZ, is also used to treat recurrent glioma. However, several mechanisms of cellular resistance to cisplatin restrict therapy efficiency. In that sense, enhanced DNA repair, high glutathione levels and functional p53 have a critical role on cisplatin resistance. In this work, we explored several mechanisms of cisplatin resistance in human glioma. We showed that cellular survival was independent of the p53 status of those cells. In addition, in a host-cell reactivation assay using cisplatin-treated plasmid, we did not detect any difference in DNA repair capacity. We demonstrated that cisplatin-treated U138MG cells suffered fewer DNA double-strand breaks and DNA platination. Interestingly, the resistant cells carried higher levels of intracellular glutathione. Thus, preincubation with the glutathione inhibitor buthionine sulfoximine (BSO) induced massive cell death, whereas N-acetyl cysteine, a precursor of glutathione synthesis, improved the resistance to cisplatin treatment. In addition, BSO sensitized glioma cells to TMZ alone or in combination with cisplatin. Furthermore, using an in vivo model the combination of BSO, cisplatin and TMZ activated the caspase 3-7 apoptotic pathway. Remarkably, the combined treatment did not lead to severe side effects, while causing a huge impact on tumor progression. In fact, we noted a remarkable threefold increase in survival rate compared with other treatment regimens. Thus, the intracellular glutathione concentration is a potential molecular marker for cisplatin resistance in glioma, and the use of glutathione inhibitors, such as BSO, in association with cisplatin and TMZ seems a promising approach for the therapy of such devastating tumors.

Indexed as

AnimalsApoptosisBrain NeoplasmsButhionine SulfoximineCell Line, TumorCell SurvivalCisplatinDacarbazineDisease ProgressionDNA DamageDNA RepairDrug Resistance, NeoplasmFemaleGliomaGlutathioneHumansButhionine SulfoximineCisplatinDacarbazineGlutathioneTemozolomideTumor Suppressor Protein p53

Identifiers

PMID25356874
PMCPMC4649538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.